Wells Fargo & Company Aeglea Bio Therapeutics, Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.11 - $0.46 $57 - $240	522 Added 6.35%	8,746 $3,000
Q1 2023 May 12, 2023	BUY	$0.29 - $0.61 $1,647 - $3,465	5,681 Added 223.4%	8,224 $2,000
Q4 2022 Feb 13, 2023	BUY	$0.35 - $1.54 $4 - $20	13 Added 0.51%	2,543 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.38 - $0.81 $33 - $70	87 Added 3.56%	2,530 $1,000
Q2 2022 Aug 12, 2022	SELL	$0.5 - $2.66 $2,291 - $12,188	-4,582 Reduced 65.22%	2,443 $1,000
Q1 2022 May 16, 2022	SELL	$1.87 - $4.77 $26,754 - $68,244	-14,307 Reduced 67.07%	7,025 $16,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $66,920 - $160,990	19,120 Added 864.38%	21,332 $101,000
Q2 2021 Aug 16, 2021	SELL	$6.32 - $8.38 $60,792 - $80,607	-9,619 Reduced 81.3%	2,212 $16,000
Q1 2021 May 13, 2021	SELL	$6.76 - $8.57 $177,287 - $224,756	-26,226 Reduced 68.91%	11,831 $94,000
Q4 2020 Feb 09, 2021	BUY	$7.02 - $9.83 $38,216 - $53,514	5,444 Added 16.69%	38,057 $300,000
Q3 2020 Nov 05, 2020	SELL	$6.51 - $9.33 $8,176 - $11,718	-1,256 Reduced 3.71%	32,613 $232,000
Q2 2020 Aug 13, 2020	SELL	$4.01 - $11.04 $138,874 - $382,337	-34,632 Reduced 50.56%	33,869 $313,000
Q1 2020 May 14, 2020	BUY	$3.51 - $8.48 $240,438 - $580,888	68,501 New	68,501 $319,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.